You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. An HIV Vaccine Strategy Based on Priming with rVSV Expressing FLSC

    SBC: PROFECTUS BIOSCIENCES, INC.            Topic: R

    DESCRIPTION Based on the prevailing evidence we believe that a highly effective vaccine for HIV prophylaxis must induce long lasting broadly cross reactive antibody responses to envelope that exhibit antiviral activity as well as multi antigen polyfunctional CD and CD T cell responses that produce antiviral chemokines and cytokines and are possibly biased towards an effector memory phenot ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Aptamer-Based Detection of Cardiac Biomarker Glycosylation States Using APT-SNAP

    SBC: Proteovista LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Aptamer Based Detection of Cardiac Biomarker Glycosylation States Using APT SNAP Arrays PIs Christopher L Warren and Mary S Ozers The presence of cardiac related biomarkers in patient biospecimens can provide important insight into diagnosis of cardiovascular disease its progression and optimal therapies for treatment Most of the cardiac biomarkers in cli ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a novel highly effective influenza vaccine

    SBC: FLUGEN INC            Topic: NIAID

    DESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Staphylococcus aureus is a Gram positive human pathogen that causes a wide range of infections from skin and soft tissue infections SSTI to life threatening sepsis and pneumonia The pathogenicity of S aureus is dependent on numerous virulence factors including cell surface proteins and polysaccharides as well as secreted toxins An important group of thes ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Substrate to Amplify Growth Factor Impact on hPSC Differentiation

    SBC: PRIMORIGEN BIOSCIENCES INC.            Topic: 300

    DESCRIPTION provided by applicant Primorigen Biosciences R Project Abstract Primorigen will use SBIR funds to develop a paradigm changing technology for expansion and directed differentiation of human pluripotent stem cells hPSCs using a novel peptide that dramatically reduces costs by amplifying the impact of endogenous growth factors and minimizing the need for exogenous growth factors Th ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. SMART: A Breath-based Adherence Technology to Monitor HIV Microbicide Gel Use

    SBC: XHALE, INC.            Topic: 105

    DESCRIPTION provided by applicant In HIV pre exposure prophylaxis PrEP trials sub optimal oral and microbicide adherence has precluded accurate estimation of drug efficacy Measurement of adherence is a major unmet challenge Other objective measures of adherence in microbicide trials have been tested but none measure the actual use of the product We propose to rapidly develop an alternati ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Automating mosquito microdissection for a malaria PfSPZ vaccine

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION Malaria causes andgt million clinical cases and million deaths annually is responsible for andgt loss of GDP in Africa and is a serious concern for travelers and military personnel A highly effective vaccine is desperately needed and radiation attenuated Plasmodium falciparum Pf sporozoites SPZ and non attenuated PfSPZ with chloroquine chemoprophylaxis ChemoProphylax ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Long-term anti-angiogenic activity of intravitreal ellipsoid particles for NVAMD

    SBC: Asclepix Therapeutics, Inc.            Topic: N

    DESCRIPTION provided by applicant Long term anti angiogenic activity of intravitreal ellipsoid particles for NVAMD Niranjan B Pandey Ph D PI Aleksander S Popel Ph D Co I Jordan J Green Ph D Co I Peter A Campochiaro M D Co I of subaward Project Summary Current therapies for wet age related macular degeneration AMD target vascular endothelial growth factors VEGFA and pla ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. MASS PRODUCTION OF PERSONALIZED HUMAN ENGINEERED HEART TISSUES

    SBC: Invivosciences, Inc.            Topic: 200

    DESCRIPTION provided by applicant Cardiomyopathy has various forms including hypertrophic cardiomyopathy HCM in prevalence could cause sudden cardiac death in athletes Dilated Cardiomyopathy DCM in prevalence results in an enlarge left ventricle Arrhythmogenic Right Ventricular Dysplasia Cardiomyopathy ARVD C in prevalence causes cardiac fibrosis Yearly over $ ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government